Additionally, while we have demonstrated the adjunctive effect of IDO inhibition with cART here, and with anti-TB therapy (ATT) earlier (19), we would, in the future, need to show the effectiveness of this HDT strategy adjunctive to simultaneously administered ATT/cART, since clinical recommendations require concurrent treatment of most PLHIV with ATT/cART. Here, IDO1 is linked to tuberculosis.